Boehringer Ingelheim has launched a new artificial intelligence (AI) and machine learning (ML) centre in London, representing the company’s latest move to drive improved patient outcomes through the technologies’ application.
Part of a £150m ($202.7m) investment being made over a 10-year period as part of Boehringer’s commitments in AI across R&D, the life sciences giant anticipates that the latest Computational Innovation site will lead to an improved understanding of the biology that drives patient outcomes and the identification of biological mechanisms with a higher probability of success.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Joining Boehringer’s existing AI-focused sites in the US, Austria, and Germany, the company said that the King’s Cross, London site will enable it to “move faster” and “make smarter decisions” in bringing new therapies to patients with unmet medical needs.
Meeting this aim will involve the development of foundational AI approaches to understand patient journeys, discover biological mechanisms that drive patient outcomes, and identify the primary causes of disease in order to discover and develop targeted medicines, Boehringer added.
With the new site officially opening today (20 April), Boehringer anticipates that it will have the first 50 AI experts in place by the end of 2027.
Paola Casarosa, global head, innovation unit at Boehringer Ingelheim, commented: “Establishing a presence in London allows us to leverage the UK’s rich data resources and infrastructure, while connecting with world‑class talent across academia, biotechnology and AI ecosystems to enable innovation for patient benefit.”
Alongside the London Cancer Hub’s announcement of a $1bn expansion to its Sutton-based site in February 2026, Boehringer’s new site should resonate with the city’s ambition to become a global life sciences hub. In turn, Boehringer’s investment in the UK could provide further relief for the sector following US pharma giant MSD’s (Merck & Co) decision to scrap its £1bn UK expansion plans in September 2025 due to discontent over the UK government’s investment in the pharma and broader life sciences sector.
Commenting on Boehringer’s site opening, UK science minister, Lord Patrick Vallance, said: “AI is unlocking opportunities to advance discovery in life sciences like never before and Boehringer’s decision to open its new hub in King’s Cross will ensure they can both access and contribute to a flourishing base for innovation in London.”
